Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Franklin McGuire

Pulmonary Disease Hickory, NC Medical Doctor

NPI 1467419358 CMS profile 111121

415 N Center St, Suite 203, Hickory, NC 28601

Open in the dashboard

General payments

$6,710

235 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Franklin McGuire of Hickory, NC is reported in the CMS Open Payments database as having received $6,710 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,416 71
2024 General $475 13
2023 General $470 24
2022 General $669 29
2021 General $480 26
2020 General $484 22
2019 General $2,715 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Franklin McGuire
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Franklin McGuire were reported at $1,416. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Franklin McGuire Pulmonary Disease median Middle half National median
2019 $2,715 $377 $109–$1,340 $163
2020 $484 $230 $56–$907 $114
2021 $480 $269 $68–$1,072 $132
2022 $669 $390 $100–$1,457 $149
2023 $470 $419 $114–$1,659 $160
2024 $475 $476 $123–$1,818 $164
2025 $1,416 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pulmonx Corporation $2,084 15 payments
  2. AstraZeneca Pharmaceuticals LP $605 35 payments
  3. Noah Medical Corporation $496 16 payments
  4. GlaxoSmithKline, LLC. $432 26 payments
  5. Actelion Pharmaceuticals US, Inc. $327 13 payments
  6. Mylan Specialty L.P. $315 20 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $304 8 payments
  8. Insmed, Inc. $247 13 payments
  9. Regeneron Healthcare Solutions, Inc. $227 9 payments
  10. Viatris Specialty LLC $165 10 payments
  11. Other $1,506 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,021 228 payments
  2. Travel and Lodging $1,623 3 payments
  3. Education $67 4 payments
Products named General payments · program years 2019–2025
  1. Pulmonx Endobronchial Valve EBV $1,976 9 payments
  2. GALAXY $496 16 payments
  3. YUPELRI $385 23 payments
  4. FASENRA $304 17 payments
  5. Arikayce $230 12 payments
  6. OFEV $212 7 payments
  7. NUCALA $202 13 payments
  8. OPSUMIT $185 7 payments
  9. UPTRAVI $169 7 payments
  10. TRELEGY ELLIPTA $162 9 payments
  11. Other $3,094 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,049

Median for Pulmonary Disease: 936

Drug cost

$292,471

Median for Pulmonary Disease: $487,987

Branded share of claims

75.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 160 $120,812
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 54 $43,400
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 43 $21,694
Spiriva Respimat Tiotropium Bromide Brand 35 $20,184
Symbicort Budesonide/Formoterol Fumarate Brand 69 $19,051
Roflumilast Generic 70 $10,712
Incruse Ellipta Umeclidinium Bromide Brand 23 $9,338
Breo Ellipta Fluticasone/Vilanterol Brand 22 $8,739
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 15 $6,898
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 36 $6,828

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$63,036

Medicare's payments for the services billed

Medicare patients

245

Average age 74

Services billed

1,046

129 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 71%
Arthritis 50%
Ischemic heart disease 49%
Heart failure 40%
Diabetes 35%
Chronic kidney disease 35%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —
Arikayce
  • Insmed, Inc. $41
$41 — —
NUCALA
  • GlaxoSmithKline, LLC. $19
$19 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $19
$19 54 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record